CELSENTRI DIN 02299852
Health Canada record
| Active ingredient(s) | MARAVIROC 300 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J05AX09 MARAVIROC |
| Original market date | 26-Sep-2007 |
| Current status date | 30-Aug-2014 |
| Source | Health Canada DPD |
Establishment licence of the holder
ViiV Healthcare ULC — licence 101800, currently licensed, last inspection rating C (2025-09-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing MARAVIROC
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02299844 | CELSENTRI | VIIV HEALTHCARE ULC | Tablet | MARAVIROC 150 MG | Marketed |
| 02561921 | WAYMADE-MARAVIROC | WAYMADE CANADA INC. | Tablet | MARAVIROC 150 MG | Marketed |
| 02561948 | WAYMADE-MARAVIROC | WAYMADE CANADA INC. | Tablet | MARAVIROC 300 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 16100 | 2014-08-29 | Supplement to a New Drug Submission (SNDS) | ADDITION OF LONG-TERM DATA FROM THREE PHASE 2B/3 TRIALS AND UPDATES TO THE PM IN THE ADVERSE REACTION SECTION |
| 10880 | 2009-12-21 | New Drug Submission (NDS) | Manufacturer name change |
| 9043 | 2007-09-21 | New Drug Submission (NDS) |
International API supply for MARAVIROC
5 active FDA Drug Master Files.
Request a quote for CELSENTRI